Pablo Aguirre

Mr. Pablo Aguirre

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
Liseth Rubí Aldaba-MuruatoLiseth Rubí Aldaba-Muruato
Liseth Rubí Aldaba-Muruato
SBSandra Sánchez Barbosa
Sandra Sánchez Barbosa
VRVíctor Hugo Rodríguez-Purata
Víctor Hugo Rodríguez-Purata
GCGeorgina Cabrera-Cruz
Georgina Cabrera-Cruz
EREstefany Rosales-Domínguez
Estefany Rosales-Domínguez
JMJosé Roberto Macías-Pérez
José Roberto Macías-Pérez
Tert-butylhydroquinone (TBHQ) is a synthetic food antioxidant with biological activities, but little is known about its pharmacological benefits in liver disease. Therefore, this work aimed to evaluate TBHQ during acute liver damage induced by CCl4 (24 h) or BDL (48 h) in Wistar rats. It was found that pretreatment with TBHQ prevents 50% of mortality induced by a lethal dose of CCl4 (4 g/kg, i.p.), and 80% of BDL+TBHQ rats survived, while only 50% of the BDL group survived. Serum markers of liver damage and macroscopic and microscopic (H&E staining) observations suggest that TBHQ protects from both hepatocellular necrosis caused by the sublethal dose of CCl4 (1.6 g/kg, i.p.), as well as necrosis/ductal proliferation caused by BDL. Additionally, online databases identified 49 potential protein targets for TBHQ. Finally, a biological target candidate (Keap1) was evaluated in a proof-of-concept in silico molecular docking assay, resulting in an interaction energy of −5.5491 kcal/mol, which was higher than RA839 and lower than monoethyl fumarate (compounds known to bind to Keap1). These findings suggest that TBHQ increases the survival of animals subjected to CCl4 intoxication or BDL, presumably by reducing hepatocellular damage, probably due to the interaction of TBHQ with Keap1.

11 October 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
MSManuel Alejandro Hernández Serda
Manuel Alejandro Hernández Serda
VVVictor Hugo Vázquez-Valadez
Victor Hugo Vázquez-Valadez
Pablo AguirrePablo Aguirre
Pablo Aguirre
Nathan Marko MarkarianNathan Marko Markarian
Nathan Marko Markarian
JMJose Medina-Franco
Jose Medina-Franco
Levon AbrahamyanLevon Abrahamyan
Levon Abrahamyan
The ongoing Coronavirus Disease 19 (COVID-19) pandemic has had a profound impact on the global healthcare system. As the SARS-CoV-2 virus, responsible for this pandemic, continues to spread and develop mutations in its genetic material, new variants of interest (VOIs) and variants of concern (VOCs) are emerging. These outbreaks lead to a decrease in the efficacy of existing treatments such as vaccines or drugs, highlighting the urgency of new therapies for COVID-19. Therefore, in this study, we aimed to identify potential SARS-CoV-2 antivirals using a virtual screening protocol and molecular dynamics simulations. These techniques allowed us to predict the binding affinity of a database of compounds with the virus Mpro protein. This in silico approach enabled us to identify twenty-two chemical structures from a public database (QSAR Toolbox Ver 4.5 ) and ten promising molecules from our in-house database. The latter molecules possess advantageous qualities, such as two-step synthesis, cost-effectiveness, and long-lasting physical and chemical stability. Consequently, these molecules can be considered as promising alternatives to combat emerging SARS-CoV-2 variants.

17 September 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
VVVictor Hugo Vázquez-Valadez
Victor Hugo Vázquez-Valadez
AHAlejandro Hernández-Serda
Alejandro Hernández-Serda
MJMa. Fernanda Jiménez-Cabiedes
Ma. Fernanda Jiménez-Cabiedes
Pablo AguirrePablo Aguirre
Pablo Aguirre
IGIngrid González-Tapia
Ingrid González-Tapia
Levon AbrahamyanLevon Abrahamyan
Levon Abrahamyan
At the end of 2019, the world was struck by the COVID-19 pandemic, which resulted in dire repercussions of unimaginable proportions. From the beginning, the international scientific community employed several strategies to tackle the spread of this disease. Most notably, these consisted of the development of a COVID-19 vaccine and the discovery of antiviral agents through the repositioning of already known drugs with methods such as de novo design. Previously, methylthiomorphic compounds, designed by our group as antihypertensive agents, have been shown to display an affinity with the ACE2 (angiotensin converting enzyme) receptor, a key mechanism required for SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) entry into target cells. Therefore, the objective of this work consists of evaluating, in silico, the inhibitory activity of these compounds between the ACE2 receptor and the S1 subunit of the SARS-CoV-2 spike protein. Supported by the advances of different research groups on the structure of the coronavirus spike and the interaction of the latter with its receptor, ACE2, we carried out a computational study that examined the effect of in-house designed compounds on the inhibition of said interaction. Our results indicate that the polyphenol LQM322 is one of the candidates that should be considered as a possible anti-COVID-19 agent.